Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Other current assets

9 Months Ended

Sep. 30, 2023

Note 8 — Other current assets

Other current assets consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
Research and development credits receivable	$	40,533	$	30,162
Prepayments		11,973		9,472
Clinical materials		1,290		1,279
VAT receivable		1,372		490
Other current assets		1,683		1,927
	$	56,851	$	43,330